State-of-the-art immunogenicity evaluation in phase 3 confirmatory study (EGALITY) with etanercept biosimilar GP2015

J Eur Acad Dermatol Venereol. 2018 Apr;32(4):e130-e132. doi: 10.1111/jdv.14632. Epub 2017 Nov 6.

Authors

J Poetzl¹, I Arlt¹, O von Richter², H Wöhling², M Afonso², G Schaffar¹

Affiliations

¹ Bioanalytics, Hexal AG, Oberhaching, Germany.
² Clinical Development, Biopharmaceuticals, Hexal AG, Holzkirchen, Germany.

PMID: 29024096
DOI: 10.1111/jdv.14632

No abstract available

Publication types

Clinical Trial, Phase III
Letter

MeSH terms

Biosimilar Pharmaceuticals / therapeutic use*
Dermatologic Agents / immunology*
Dermatologic Agents / therapeutic use*
Etanercept / immunology*
Etanercept / therapeutic use*
Humans
Limit of Detection
Psoriasis / drug therapy

Substances

Biosimilar Pharmaceuticals
Dermatologic Agents
GP2015
Etanercept